Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gentiopicroside
- Development stage
- Phase 3
- Lead developer
- Shaanxi Xida Yonghe Technology Development
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Qinlongkusu Injection is a botanical-derived small molecule therapeutic developed by Shaanxi Xida Yonghe Technology Development for the treatment of chronic hepatitis B and associated jaundice. The active pharmaceutical ingredient is gentiopicroside (also known as gentiopicrin), a secoiridoid glycoside primarily extracted from the roots of *Gentiana macrophylla* (Qin Jiao). Gentiopicroside exerts hepatoprotective effects by modulating inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and inhibiting the NF-κB signaling pathway, thereby reducing hepatic inflammation and promoting the recovery of liver function. In clinical trials in China, it has been evaluated as a treatment for jaundice-type chronic hepatitis B, often compared against traditional therapies like Yinzhihuang Injection to assess its efficacy in reducing serum bilirubin levels and improving clinical symptoms.
- Brand names
- Qinlongkusu
- Other names
- gentiopicrinQinlongkusu Injection
02
Targets
IL-6 (Interleukin 6)NF-κBTNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on gentiopicroside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gentiopicroside.